Msi-1 is a Predictor of Survival and a Novel Therapeutic Target in Colon Cancer

Li, Dawei; Peng, Xiao; Yan, Dongwang; Tang, Huamei; Huang, Fei; Yang, Yinxue; Peng, Zhihai

doi:10.1245/s10434-011-1567-9

Cited by 60 publications

(62 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a significant association was found between Msi-1 expression and overall survival in young patients. Our present findings in young patients with gastric cancer are consistent with studies of Msi-1 expression in other tumor types (23)(24)(25). In breast cancer patients, Msi-1 overexpression may be related to lymph node metastasis and shorter survival (23), and in human glioma, may be related to the degree of malignancy and proliferative activity (24).…”

Section: Discussionsupporting

confidence: 90%

“…In breast cancer patients, Msi-1 overexpression may be related to lymph node metastasis and shorter survival (23), and in human glioma, may be related to the degree of malignancy and proliferative activity (24). In patients with colon cancer, Msi-1 is associated with advanced cancer stage, metastasis and poor survival (25). Knockdown of Msi-1 with Msi-1 siRNA resulted in reduced colon cancer cell proliferation, cancer growth arrest in xenografts, and increased apoptosis alone and in combination with radiation therapy in athymic nude mice in vivo (14).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Musashi-1 expression and clinicopathological significance in young gastric cancer patients: A matched case-control study

Choi

Bae

Lee

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Musashi-1 (Msi-1) is proposed to be a marker of progenitor cells in the human gastric mucosa. We examined Msi-1 expression and localization in surgical specimens of gastric cancer in young patients using immunohistochemistry and tested associations of Msi-1 expression with clinicopathological features. Patients (n=611) with gastric cancer who underwent radical gastrectomy were included in the present study. To minimize confounding effects, we matched 26 gastric cancer patients 30 years of age or younger (age ≤30) with 26 patients 60 years of age or older (age ≥60). The groups were matched by gender, tumor histological type and tumor stage. Gastric cancer in the younger patients was significantly associated with female gender and with diffuse histological type, compared with 585 gastric cancer patients older than 31 years. Msi-1 expression was more frequently upregulated in gastric cancer in young patients than in patients older than 60 years. Msi-1 expression was significantly associated with diffuse histological type, depth of tumor invasion, lymph node metastasis and tumor stage in the 26 young patients with gastric cancer. Univariate Kaplan-Meier survival analysis identified Msi-1 expression as a significantly negative factor in the survival of young gastric cancer patients. However, Msi-1 expression was not significantly associated with survival in the 26 matched older patients. According to mucin phenotype, the gastric foveolar type predominated in Msi-1-positive gastric cancers. Our principal findings included a significantly higher level of Msi-1 expression in younger gastric cancer patients compared to older ones, and a probable association of tumor Msi-1 expression in young gastric cancer patients with more aggressive tumor type.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Musashi-1 expression and clinicopathological significance in young gastric cancer patients: A matched case-control study

Choi

Bae

Lee

et al. 2014

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…As vascular and neural infiltrations are known to be ominous prognostic factors, their identification has great clinical relevance. Increasing evidence shows that perineural invasion or the neural cell adhesion molecule might be a prognostic factor for various cancers, such as bile duct cancer (Seki et al 1993, Kayahara et al 1994, gallbladder cancer (Seki et al 1995), breast cancer (Lo et al 1997), esophageal cancer (Tanaka et al 1998), pancreatic cancer (Pour et al 2003, Levy et al 2006, Kayahara et al 2007, prostate cancer (Li et al 2003), and colorectal cancer (Gavert et al 2005, Zhou et al 2009, Li et al 2011. Importantly, a recent report has shown that the severity of the neural invasion in rectal adenocarcinoma is an important factor in a scoring system to assess the prognostic value, showing high correlation with localization and severity (Ceyhan et al 2010).…”

Section: Introductionmentioning

confidence: 99%

GDNF increases cell motility in human colon cancer through VEGF–VEGFR1 interaction

Huang

Chen

Chiu

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophic factor, has been shown to affect cancer cell metastasis and invasion. However, the molecular mechanisms underlying GDNF-induced colon cancer cell migration remain unclear. GDNF is found to be positively correlated with malignancy in human colon cancer patients. The migratory activities of two human colon cancer cell lines, HCT116 and SW480, were found to be enhanced in the presence of human GDNF. The expression of vascular endothelial growth factor (VEGF) was also increased in response to GDNF stimulation, along with VEGF mRNA expression and transcriptional activity. The enhancement of GDNF-induced cancer cell migration was antagonized by a VEGF-neutralizing antibody. Our results also showed that the expression of VEGF receptor 1 (VEGFR1) was increased in response to GDNF stimulation, whereas GDNF-induced cancer cell migration was reduced by a VEGFR inhibitor. The GDNF-induced VEGF expression was regulated by the p38 and PI3K/Akt signaling pathways. Treatment with GDNF increased nuclear hypoxia-inducible factor 1 a (HIF1a) accumulation and its transcriptional activity in a time-dependent manner. Moreover, GDNF increased hypoxia responsive element (HRE)-containing VEGF promoter transcriptional activity but not that of the HRE-deletion VEGF promoter construct. Inhibition of HIF1a by a pharmacological inhibitor or dominant-negative mutant reduced the GDNF-induced migratory activity in human colon cancer cells. These results indicate that GDNF enhances the migration of colon cancer cells by increasing VEGF-VEGFR interaction, which is mainly regulated by the p38, PI3K/Akt, and HIF1a signaling pathways.

show abstract

“…Musashi-1 marker (Msi-1) is considered by some authors as a CSC marker in colon and stomach cancer (Kuang et al, 2013;Li et al, 2011). CD44 protein, which is an adhesion molecule, is also considered as a CSC marker.…”

Section: Int J Adv Res 5(12) 118-135mentioning

confidence: 99%

Morphological and Immunohistochemical Classification Aspects of Serrated Formations of the Large Intestine.

Oleynikova¹,

Kharlova²,

Malkov³

et al. 2017

IJAR

View full text Add to dashboard Cite

Msi-1 is a Predictor of Survival and a Novel Therapeutic Target in Colon Cancer

Abstract: Our study provides the basis to explore the use of Msi-1 as a novel prognostic biomarker in colon cancer patients. Aberrant overexpression of Msi-1 during metastasis of colon cancer also suggests that it is a potential therapeutic target.

Cited by 60 publications

References 23 publications

Musashi-1 expression and clinicopathological significance in young gastric cancer patients: A matched case-control study

Musashi-1 expression and clinicopathological significance in young gastric cancer patients: A matched case-control study

GDNF increases cell motility in human colon cancer through VEGF–VEGFR1 interaction

Morphological and Immunohistochemical Classification Aspects of Serrated Formations of the Large Intestine.

Contact Info

Product

Resources

About